학술논문

HERIZON-GEA-01: Zanidatamab plus chemo +/- tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
Document Type
Journal
Source
FUTURE ONCOLOGY; AUG 24 2022, 12p.
Subject
Language
English
ISSN
17448301